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Summary
 
The merozoite surface protein 1 (MSP1) has emerged as a leading malaria vaccine candidate at
the erythrocytic stage. Recombinant bacillus Calmette-Guérin (rBCG), which expressed a
COOH-terminal 15-kD fragment of MSP1 of 
 
Plasmodium yoelii
 
 (MSP1-15) as a fusion protein
with a secretory protein of 
 
Mycobacterium kansasii
 
, was constructed. Immunization of mice with
this rBCG induced a higher degree of protection against blood-stage parasite infection than
with recombinant MSP1-15 in the RIBI adjuvant (RIBI ImmunoChem Research, Inc.,
Hamilton, MT) or incomplete Freund’s adjuvant systems. We studied the mechanism of pro-
tection induced by MSP1-15, and found that interferon (IFN)-
 
g
 
 had a major role in protection
in all adjuvant systems we examined. Mice that produced low amounts of MSP1-15 stimulated
IFN-
 
g
 
 and could not control parasite infection. The antibody against MSP1-15 did not play a
major role in protection in this system. After parasite infection, immunoglobulin G2a antibod-
ies, which had been produced by IFN-
 
g
 
 stimulation, were induced and subsequently played an
important role in eradicating parasites. Thus, both cellular and humoral immune responses
were essential for protection from malaria disease. These data revealed that BCG is a powerful
adjuvant to induce such a protective immune response against malaria parasites.
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M
 
alaria is still a serious problem in tropical countries.
500 million people suffer from malaria, and deaths
total 2.7 million a year (1). The main hope for controlling
this disease is to develop effective vaccines. Several protec-
tive antigens have been identified, and analysis of epitopes
in each of them has been explored (1). However, to pro-
mote and safely prolong the immune response, the devel-
opment of effective adjuvants is required.
Widespread use of the Calmette-Guérin bacillus (BCG)
 
1
 
has demonstrated some advantages, such as excellent im-
mune adjuvant activity, long-persisting effects, safety, and
low cost, leading us to use it as a vaccine vehicle for deliv-
ering foreign antigens. A transformation system for myco-
bacteria enabled us to express a foreign gene in BCG (2).
With this system, we used the 
 
a
 
 antigen of 
 
Mycobacterium
kansasii
 
 (
 
a
 
-k) to secrete a foreign antigen from BCG (3).
By using a promoter from heat shock protein, two groups
succeeded in expressing gag, pol, and env of HIV-1 in
BCG and induced humoral and cellular responses in im-
munized mice (4, 5). Subsequently, varieties of the expres-
sion system have also been reported (6–12). In recent years,
protective humoral responses against 
 
Borrelia burgdorferi
 
 (13,
14) and 
 
Streptococcus pneumoniae 
 
(15) were efficiently in-
duced using the recombinant (r)BCG system. This efficacy
was seen only when the protective antigens were secreted
from BCG.
Arguments supporting BCG as a suitable vector for a
malaria vaccine have been raised. First, BCG immunization
alone could provide nonspecific resistance to malaria infec-
tion in mice (16, 17). Second, the use of a tuberculin puri-
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fied protein derivative–parasite antigen conjugate and live
BCG priming induced protection against a malaria parasite
without strong adjuvants (18). Therefore, the rBCG system
is expected to be an excellent system for malaria vaccine
development. Trials have been progressing, though a suc-
cessful result has not yet been obtained (10, 19).
The merozoite surface protein 1 (MSP1) is one of the
leading vaccine candidates at the erythrocytic stage. This
molecule has been identified in almost all of the 
 
Plasmodium
 
species that infect humans (20, 21), simians (22, 23), and
rodents (24–26). Molecular mass ranges from 185 to 250 kD.
Protective immunity induced by vaccination with MSP1
was demonstrated initially in the 
 
Plasmodium yoelii
 
 model
(24). Subsequently, this finding was also confirmed in a
nonhuman primate model using MSP1 from 
 
Plasmodium
falciparum
 
, the most virulent human malaria parasite (27–
34). MSP1 is proteolytically cleaved into several fragments
by two processing steps (35–39). Only a COOH-terminal
19-kD fragment of MSP1 (MSP1-19) remains on the
merozoite surface during invasion into a new erythrocyte
(35). The COOH-terminal fragment contains a series of
cysteine residues that are conserved among various 
 
Plasmo-
dium
 
 species. Structural examination showed that it pos-
sessed two epidermal growth factor–like domains (36).
Antibodies specific to MSP1-19 inhibited invasion of mero-
zoites into erythrocytes in vitro
 
 
 
(35, 40, 41). Some MSP1-
19–specific antibodies inhibited the protease-mediated sec-
ondary processing of MSP1 (42). In rodent models, an mAb
which protected mice against infection in passive transfer ex-
periments recognized MSP1-15 (43–45). It has been re-
ported that immunization with MSP1-15 from 
 
P. yoelii
 
 can
protect mice against lethal infection (46). In light of the re-
ports described above, the COOH-terminal fragment of
MSP1 should be an attractive component of a subunit vac-
cine against malaria. Therefore, the combination of the
COOH-terminal polypeptide and BCG was expected to be
a powerful tool for developing an effective malaria vaccine.
In this study, we first constructed rBCG secreting
MSP1-15 as a fusion protein with 
 
a
 
-k (
 
a
 
-k–MSP1-15),
and found that rBCG could induce significant protection
against a 
 
P
 
.
 
 yoelii
 
 challenge in immunized C3H/He mice.
This system was much more efficient than other artificial
adjuvants for MSP1-15 in C3H/He mice. We studied ex-
tensively the mechanism of protection in immunized mice,
and found that IFN-
 
g
 
 played an important role in this pro-
tection. Antibodies against the parasite, induced in the
course of infection, also eventually contributed to the sub-
sequent protection.
 
Materials and Methods
 
Plasmids and Bacterial Strains.
 
BCG Tokyo was used as a host
for plasmid pSO246 (47) and its derivatives. BCG Tokyo and its
transformants were grown in Middlebrook 7H9 broth (Difco Lab-
oratories, Inc., Detroit, MI) supplemented with 10% albumin-
dextrose-catalase (ADC) enrichment (Difco Laboratories, Inc.)
and 0.5% Tween 80 (7H9 ADC medium). rBCG was selected by
growing on Middlebrook 7H10 agar (Difco Laboratories, Inc.)
containing 10% oleic acid-albumin-dextrose-catalase (OADC)
enrichment (Difco Laboratories, Inc.), 0.5% glycerol, 400 U/ml
penicillin, and 100 
 
m
 
g/ml cycloheximide (7H10 OADC agar).
 
Escherichia coli 
 
strain XL1-blue was used as a host for plasmid
pGEX2T (Pharmacia Biotech, Inc., Uppsala, Sweden), pMALC2
(New England Biolabs, Inc., Beverly, MA), pBluescript SK(
 
1
 
)
(Stratagene, La Jolla, CA), and their derivatives. The 
 
E
 
.
 
 coli
 
 strain
was grown in TY broth with or without 2% glucose.
 
Animals.
 
C3H/He and A/J female mice were purchased from
Japan SLC (Hamamatsu, Japan). C57BL/6 female mice were pur-
chased from Charles River Laboratories (Wilmington, MA).
 
Construction of Expression Vectors to Secrete MSP1-15 from BCG.
 
An MSP1-15 gene segment (amino acids 1618–1722 [48]) was
amplified by PCR targeted to the genomic DNA of 
 
P
 
.
 
 yoelii
 
17XL. Primers used to amplify the MSP1-15 gene were primer A
(for the sense strand), 5
 
9
 
-CCctcgagCATAGCCTCAATAGCT,
and primer B (for the antisense strand), 5
 
9
 
-CCctcgagCCCAT-
AAAGCTGGAAG. The added sequence indicated by small let-
ters refers to sites recognized by restriction enzymes. pKH20,
which included an 
 
a
 
-k gene (49), was then digested with both
BamH1 and HindIII. The 2-kbp BamH1-HindIII fragment con-
taining the 
 
a
 
-k gene was inserted into the same sites of pBlue-
script SK (
 
1
 
). This plasmid was designated pBSSKH20. The
DNA fragment amplified with primers A and B was digested with
Xho1 and inserted into the same site of pKH20. This plasmid was
designated pUCMSP1-15. It was then digested with BamHI and
HindIII. The 2.4-kbp fragment containing an 
 
a
 
-k–MSP1-15 hy-
brid gene was inserted into the same sites of pSO246 (47). The fi-
nal construct was designated pSOMSP1-15 (for the construction
map, see Fig. 1 
 
A
 
). It was transformed into BCG Tokyo by elec-
troporation as described previously (19).
 
Expression of MSP1-15 by Two Systems in E. coli.
 
To prepare
the DNA encoding recombinant fusion protein of 
 
Schistosoma
japonicum
 
 glutathione 
 
S
 
-transferase (GST) and MSP1-15 (GST–
MSP1-15), the oligonucleotides 5
 
9
 
-GGggatccCACATAGCCT-
CAATAGCT (for the sense strand) and 5
 
9
 
-CCCgaattcTCCCAT-
AAAGCTGGAAG (for the antisense strand) were synthesized.
PCR was performed using the above-described primers targeting
genomic DNA from 
 
P
 
.
 
 yoelii
 
 17XL. Amplified DNA was digested
with both BamHI and EcoRI. It was then inserted into the same
site of pGEX2T, and the final construct was transformed into 
 
E
 
.
 
coli
 
. Next, to prepare the DNA encoding the recombinant fusion
protein of maltose binding protein (MBP) and MSP1-15 (MBP–
MSP1-15), the oligonucleotides 5
 
9
 
-GGGgaattcCACATAGCC-
TCAATAGCT (for the sense strand) and 5
 
9
 
-GGGctgcagTCCC-
ATAAAGCTGGAAG (for the antisense strand) were synthesized.
The DNA amplified using the above-described primers was di-
gested with both EcoR1 and PstI. It was then inserted into the
same site of pMALC2, and transformed into 
 
E
 
.
 
 coli
 
. GST–MSP1-15
and MBP–MSP1-15 were isolated from bacterial lysates by
affinity chromatography according to the manufacturer’s instruc-
tions (Pharmacia Biotech, Inc., and New England Biolabs, Inc.).
 
Polyclonal Antibody Preparation.
 
The polyclonal antibody (PAb)
against 
 
P
 
.
 
 yoelii
 
 17XL was prepared from mice which were re-
peatedly infected with 
 
P
 
.
 
 yoelii 
 
17XL. The rabbit anti–
 
a
 
-k PAb
was provided by Dr. Matsuo (Central Research Laboratories, Aji-
nomoto Co. Inc., Kawasaki, Japan [49]).
 
Immunization of C3H/He Mice with rBCG.
 
C3H/He mice at
7–10 wk of age were immunized intravenously with 10
 
6
 
 CFU of
BCG transformed with pSOMSP1-15 (rBCGMSP1-15) in 200 
 
m
 
l
of PBS containing 0.1% Tween 80 (PBS-T80). A control group
of mice was injected with 10
 
6
 
 CFU of BCG in 200 
 
m
 
l of PBS- 
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T80 or PBS-T80 only. After 30 d, the same amount of each sam-
ple was injected intraperitoneally to boost the immune response.
Before 1 wk from parasite challenge, sera were collected from the
eye veins of immunized mice and pooled at 
 
2
 
80
 
8
 
C until use.
 
Immunization with GST–MSP1-15 in Artificial Adjuvants.
 
Each kind of mouse was immunized with 10 
 
m
 
g i.p. of GST–
MSP1-15 in either IFA or the Rivi adjuvant system (RAS). The
control group was injected with 10 
 
m
 
g of GST in the same way.
3 wk after the first vaccination, a second immunization was car-
ried out with the same amounts of each sample.
 
Measurement of Antibody Titer against MSP1-15 and Blood-stage
Parasite.
 
The titer of whole immunoglobulins (Igs), IgE, IgM,
IgG1, IgG2a, IgG2b, and IgG3 antibodies against MSP1-15 and
 
P
 
.
 
 yoelii
 
 lysate was measured by ELISA as follows. Each well of a
microtiter plate was coated with 10 
 
m
 
g/ml of MBP–MSP1-15 or
 
P
 
.
 
 yoelii
 
 lysate (blood-stage) in 100 
 
m
 
l of borate-buffered saline
(BBS: 167 mM borate, 134 mM NaCl, pH 8.0) by incubation at
room temperature for 2 h. The wells were washed once with
BBS by shaking on the automatic ELISA washer. The wells were
then blocked with 200 
 
m
 
l of 3% BSA in BBS for 1 h at room
temperature and washed with BBS containing 0.5 M NaCl (HS-
BBS). 100 
 
m
 
l of each serum diluted to 1:100 with BBS containing
1% BSA was added to individual wells and incubated at 37
 
8
 
C for
30 min. After washing with HSBBS seven times, each well was
filled with 100 
 
m
 
l of peroxidase-conjugated anti–mouse Ig, IgM,
IgE, IgG1, IgG2a, IgG2b, or IgG3 (Organon Teknika-Cappel,
Durham, NC) antibodies diluted to 1:1,000 with BBS containing
1% BSA, and incubated at 37
 
8
 
C for 30 min. After washing with
HSBBS seven times and once with BBS, 100 
 
m
 
l of a solution of
0.4 mg/ml of 
 
o
 
-phenylenediamine dihydrochloride in 80 mM
citrate-phosphate, pH 5.0, was added to the wells. OD was mea-
sured at 492 nm.
 
Challenge Infection of P. yoelii 17XL.
 
All mice were challenged
with 10
 
4
 
 
 
P
 
. yoelii 17XL–parasitized erythrocytes intravenously or
intraperitoneally 1 mo after the final immunization. The course
of infection was monitored by microscopic examination of tail-
blood smears stained with Giemsa.
Immune Sera Passive Transfer Experiment. Sera were collected
from mice immunized with rBCGMSP1-15 or GST-MSP1-15
in RAS at 1 wk before or 30 d after parasite challenge. A group of
naive C3H/He mice was given 200 ml of serum intraperitoneally.
1 h later, mice were challenged with 104 P. yoelii 17XL–parasit-
ized erythrocytes intraperitoneally.
Measurement of Cytokine Production. 1 mo after the final im-
munization, mice were killed, and spleens were removed from at
least three mice of each group. Red cells were lysed by Tris–
ammonium buffer and washed with RPMI 1640 medium. Spleen
cells were suspended in RPMI 1640 medium with 10% FCS con-
taining 5 mg/ml of MBP or MBP–MSP1-15 at a concentration of
106/ml, and 200 ml of suspension was put into a round-bottomed
well (Iwaki Glass Co., Ltd., Funabashi, Japan). The plate was in-
cubated at 378C for 48 h, and supernatants were then collected
and analyzed. Measurement of IFN-g and IL-4 was carried out
using ELISA kits (Genzyme Corp., Cambridge, MA) as described
in the kit instructions.
Neutralization of IFN-g. For neutralization of IFN-g, mice
were treated with 100 mg i.p. of the rat anti–mouse IFN-g mAb
(Endogen, Inc., Cambridge, MA) 2 d before, the day of, and 2 d
after the challenge infection. As controls, mice were treated with
rat IgG (Endogen, Inc.) in the same way.
Treatment of Immunized Mice with Inhibitor of Nitric Oxide Syn-
thase. Mice immunized with rBCGMSP1-15 were injected
with 250 mg/kg/d i.p. of N G-monomethyl-l-arginine (L-
NMMA) every day from 2 d before to 2 d after infection. As
controls, mice were treated with N G-monomethyl-d-arginine
(D-NMMA) in the same way.
Results
Secretion of Conformational MSP1-15 from rBCG as a Fusion
Protein with a-k. BCG was transformed with pSOMSP1-15
(Fig. 1 A), and designated rBCGMSP1-15. The rBCGMSP1-
15 was cultured for 3 wk on Sauton medium (3). After precip-
itation of proteins in culture filtrates (CF) from rBCGMSP1-
15 with 80% NH4SO4, 20 mg of the proteins was applied
to SDS-PAGE (Fig. 1 B). The proteins in the gels were vi-
sualized by staining the gel with Coomassie brilliant blue
(Fig. 1 B). The additional bands at 40 and 22 kD (lane 3)
were estimated to be a-k–MSP1-15 and its degraded prod-
uct because both anti–a-k and anti-GST–MSP1-15 PAbs
reacted to these additional bands (data not shown). It was
reported that the native structure of MSP1 is important to
induce protection (41). Therefore, we assessed whether an-
tibodies against native MSP1-15 reacted to a-k–MSP1-15.
After native PAGE, the proteins were blotted and reacted
with the PAb against blood-stage P. yoelii 17XL. The re-
sults are presented in Fig. 1 C. A strong reaction to the na-
ive sample including a-k–MSP1-15 was observed (lane 4),
Figure 1. Construction of pSOMSP1-15 (A) and detection of
secreted  a-k–MSP1-15 from rBCG by SDS-PAGE (B) and
Western blot analysis (C). (A) Plasmid map of pSOMSP1-15. P,
A promoter of the a-k gene. SS, An encoding region of the sig-
nal sequence. neo, A neomycin phosphotransferase gene. Striped
bar, MSP1-15 gene. White bar, An a-k structural gene. The ex-
perimental procedures are described in Materials and Methods.
(B) Coomassie brilliant blue–stained gels, resolved by SDS-
PAGE. Lanes are as follows: molecular mass marker (lane 1), 20
mg of secreted proteins from BCG transformed with empty plas-
mid (lane 2), and BCG transformed with pSOMSP1-15 (lane 3).
Arrows, Additional bands estimated to be a-k–MSP1-15 and its
degraded product. (C) Western blot analysis by anti–blood-stage
P. yoelii antibodies. CF from BCG transformed with empty plas-
mid (lanes 1 and 3) and from BCG transformed with pSOMSP1-15 (lanes 2 and 4) were suspended in sample buffer without SDS and 2-ME. The sam-
ples in lanes 1 and 2 were heat-denatured before PAGE. The samples were subjected to native PAGE and transferred to polyvinylidene difluoride mem-
brane. The membrane was reacted with anti–blood-stage P. yoelii sera.848 Recombinant BCG Vaccination against Malaria
but reaction to the heat-denatured sample was diminished
(lane 2). These results indicated that (a) almost all of the an-
tibodies against MSP1-15 induced by infection with P.
yoelii recognized conformational epitopes in MSP1-15; and
(b) a-k–MSP1-15 secreted from rBCGMSP1-15 formed a
similar antigenic conformation as the native MSP1-15.
GST–MSP1-15 purified from recombinant E. coli was also
recognized by antibody against conformational determi-
nants in MSP1-15, as described previously (46), as was
MBP–MSP1-15 (data not shown).
Evaluation of the Protective Efficacy Induced by MSP1-15 in
Several Adjuvants. All of the C3H/He mice immunized
with samples were challenged with 104 P. yoelii 17XL, and
the levels of protection of various adjuvants were com-
pared. All mice immunized with PBS (Fig. 2 A), GST in
RAS (Fig. 2 B), and GST in IFA (Fig. 2 C) showed detect-
able parasitemia 4 d after challenge, as expected (Fig. 2,
A–C). PBS-T80 gave results similar to PBS immunization
(data not shown). These mice developed fulminating infec-
tion with high parasitemia leading to death. When mice
were immunized with live BCG, it was of interest to see a
2–4-d delay of the onset of parasitemia, though they even-
tually developed fulminating infection and died (Fig. 2 D).
Results similar to BCG immunization were obtained when
the mice were immunized with rBCG-transformed empty
plasmids or plasmids containing only the a-k gene (data
not shown). Slight preventive effects on parasitemia were
observed when mice were immunized with GST–MSP1-
15 without adjuvant (Fig. 2 E). Combinations of a variety
of adjuvants stimulated protection by MSP1-15 (Fig. 2,
F–H). Three out of seven mice immunized with GST–
MSP1-15 in RAS (Fig. 2 F), two out of eight mice immu-
nized with GST–MSP1-15 in IFA (Fig. 2 G), and six out
of seven mice immunized with rBCGMSP1-15 (Fig. 2 H)
survived the infection. These data indicate that three of the
adjuvants examined in this study are effective for vaccina-
tion with MSP1-15, though their levels of efficacy are dif-
ferent. The rBCG system was the most effective.
IFN-g versus IL-4 Production in Spleens from Immunized
Mice. That the spleen plays an important role in host de-
fense against Plasmodium infection is well-established. We
examined the production of IFN-g as representative of
Th1-type responses and of IL-4 as representative of Th2-
type responses in spleen cells. 30 d after the final immuni-
zation, spleens were removed from mice immunized with
rBCGMSP1-15. The cells were then cultured with MBP–
MSP1-15. As controls, cells were cultured with MBP alone
or medium only. After incubation for 48 h, the cytokines
produced in the culture medium were assessed by ELISA,
and the results are presented in Fig. 3. An appreciable
amount of IFN-g, but not IL-4, was detected. Similar re-
sults were obtained using spleen cells from mice immu-
nized with GST–MSP1-15 in IFA (data not shown). These
data suggested that MSP1-15 induced IFN-g but not IL-4
in C3H/He mice regardless of the adjuvant used.
IFN-g and Nitrous Oxide Play Important Roles in Clearance
of Infection. Next, we assessed the role of IFN-g in pro-
tection against parasite infection. C3H/He mice were im-
munized with rBCGMSP1-15 and treated with IFN-g
neutralizing antibodies. The control mice were treated
with the same dose of rat IgG. The time courses of para-
Figure 2. Course of infection of P. yoelii
in individual female C3H/He mice. Mice
were immunized with PBS (A), GST in
RAS (B), GST in IFA (FIA; C), parental
BCG in PBS-T80 (D), GST–MSP1-15 in
PBS (E), GST–MSP1-15 in RAS (F),
GST–MSP1-15 in IFA (FIA; G), and
rBCGMSP1-15 in PBS-T80 (H). The im-
munization procedure is described in Mate-
rials and Methods. PBS-T80 gave results
similar to PBS immunization. y-axis, Per-
centage of infected erythrocytes. Parasitemia
was estimated from Giemsa-stained smears.
x-axis, Days from challenge. Each line
shows the course of parasitemia of an indi-
vidual mouse. d, Dead mouse. s, Self-cured
mouse. These experiments were repeated at
least three times.
Figure 3. Production of IFN-g and IL-4 in spleen cells stimulated with
control saline (gray bar), MBP (black bar), and MBP–MSP1-15 (white bar).
y-axis, Amounts of produced cytokines in the supernatants. Immunizing
samples are indicated below the x-axis. Measurements of IFN-g and IL-4
were made with the ELISA kit purchased from Genzyme Corp. (Cam-
bridge, MA). The amounts of cytokines were calculated using serial dilu-
tions of supernatants to obtain values that fell within the linear range of
the standard curve. Data are expressed as the mean 6 SD for three cul-
tures.849 Matsumoto et al.
sitemia in these experiments are presented in Fig. 4 A.
Three out of four mice in both groups developed infection.
As expected, all of the control mice cleared the infection and
were self-cured. On the other hand, three out of the four
mice treated with IFN-g neutralizing antibodies eventually
died, although an obvious difference in parasitemia from the
control group was not observed at the beginning of the infec-
tion (Fig. 4 A). It is well known that IFN-g enhances the
production of nitrous oxide (NO), which is effective against
intracellular parasites. We also assessed the role of NO by
neutralization with the inhibitor of NO synthase, L-NMMA,
in vivo. Mice were immunized with rBCGMSP1-15 and
treated with L-NMMA intraperitoneally. As shown in Fig. 4
B, three out of four control mice treated with D-NMMA
were self-cured of disease, whereas three out of four mice
treated with L-NMMA could not control the infection and
eventually died. These data indicate that both IFN-g and
NO have important roles in protection against infection in-
duced by rBCGMSP1-15 immunization.
Evaluation of the Protectiveness of the Sera before Parasite
Challenge. The humoral immune response to MSP1-15
and P. yoelii lysate was monitored by ELISA. No obvious
antibody specific to MSP1-15 was observed in mice immu-
nized with rBCGMSP1-15 before parasite challenge (Fig. 5
A, lane 3). In contrast, a high titer of MSP1-15–specific an-
tibody was observed in the sera of mice immunized with
GST–MSP1-15 in both RAS and IFA before challenge
(Fig. 5 A, lanes 7 and 9). Assessing the isotypes of these
anti–MSP1-15–specific Igs revealed that RAS stimulated
MSP1-15–specific IgM and IgG2a dominantly (Fig. 5 B,
left) and IFA stimulated IgM, IgG1, IgG2a, and IgG2b (Fig.
5 B, right). We also assessed the protective efficacy of the
sera before challenge. Naive C3H/He mice were given
0.2 ml i.p. of sera from mice before parasite challenge. 1 h
later, 104 P. yoelii–infected erythrocytes were injected in-
traperitoneally. The results showed that sera before chal-
lenge were not protective (Fig. 5 C), though the sera in-
cluded a high titer of MSP1-15–specific antibody (Fig. 5
A). This suggested that the MSP1-15–specific antibody was
not an essential factor in the protection induced by immu-
nization with both rBCGMSP1-15 and GST–MSP1-15 in
artificial adjuvants.
Evaluation of the Protectiveness of the Sera after Clearance of In-
fection. The measurements of antibody levels against P.
yoelii lysates in sera from mice after clearance of infection
were also examined. Large levels of IgM and IgG2a against
parasite antigens (Fig. 6 A) were observed. We assessed the
protective efficacy of the sera after clearance of infection and
found a strong degree of protection (Fig. 6 B, right). Similar
results were obtained in mice immunized with GST–MSP1-
15 in IFA (data not shown). These results indicated that anti-
bodies induced in the course of infection were protective.
Importance of MSP1-15–specific IFN-g Production for Protec-
tion in Other Kinds of Mice. We next assessed the influence
of different genetic backgrounds of mice on level of pro-
tection. A/J and C57BL/6 mice were immunized with
GST–MSP1-15 in RAS. Before challenge, spleen cells
were stimulated with MSP1-15, and the level of IFN-g
production was assessed. The results showed that A/J mice
immunized with GST–MSP1-15 produced higher amounts
of IFN-g than C57BL/6 mice when the cells were stimu-
lated with MSP1-15 in vitro (Fig. 7 A). Serum was ob-
tained from each mouse before challenge, and the antibody
levels against MSP1-15 and their subclasses were examined.
Figure 4. (A) Course of infection of P. yoelii in C3H/He mice immu-
nized with rBCGMSP1-15 and treated with either control rat IgG (filled
square) or anti–IFN-g neutralizing antibody (open circle). (B) Similar exper-
iments were carried out with either D-NMMA (filled triangle) or
L-NMMA (1). Each line shows the course of parasitemia of an individual
mouse. y-axis, Percentage of parasite-infected erythrocytes. x-axis, Days
after infection. d, Dead mouse. s, Self-cured mouse. Figure 5. Analysis of sera before challenge. (A) Level of MSP1-15–spe-
cific antibody in sera from mice immunized with each sample before
challenge. Lanes are as follows: 1, PBS-T80; 2, BCG in PBS-T80; 3,
rBCGMSP1-15 in PBS-T80; 4, PBS; 5, GST–MSP1-15 in PBS; 6, GST
in RAS; 7, GST–MSP1-15 in RAS; 8, GST in IFA; 9, GST–MSP1-15 in
IFA. y-axis, OD at 492 nm, after subtracting OD of the control sample.
Sera were diluted to 1:100. (B) Isotype distribution of antibodies against
MBP–MSP1-15. Serum antibodies were obtained before challenge from
mice immunized with GST (black bar) or GST–MSP1-15 (white bar) in
RAS (left) or IFA (FIA; right). The level of Igs against MBP–MSP1-15
and their distribution into IgM, IgG1, IgG2a, IgG2b, and IgG3 subclasses
were assessed by ELISA using anti–mouse subclass-specific antibodies.
(C) Passive immunity imparted by transfer of serum from mice immu-
nized with PBS (left), rBCGMSP1-15 (middle), and GST–MSP1-15 in
RAS (right). 1 h after passive transfer of 0.2 ml of each serum, mice were
challenged with 104 P. yoelii–parasitized erythrocytes intraperitoneally.
Each line shows the course of parasitemia of an individual mouse. y-axis,
Percentage of parasitemia. x-axis, Days from infection.850 Recombinant BCG Vaccination against Malaria
The data show that both strains of mice produced high levels
of MSP1-15–specific antibodies. A/J mice produced MSP1-
15–specific IgM and IgG2a antibodies, and C57BL/6 mice
produced MSP1-15–specific IgM and IgG2b antibodies
(Fig. 7 B), indicating that GST–MSP1-15 immunization
induces the production of IFN-g and IgG2a in A/J mice
but not in C57BL/6 mice. Next, the protective efficacy in-
duced by GST–MSP1-15 immunization in both strains of
mice was examined. As shown in Fig. 7 C, strong protec-
tion was induced only in A/J mice. These data again con-
firmed that the production of IFN-g induced by MSP1-15
has a major role in effective protection.
Discussion
The selection of proper antigens and adjuvants is the
most important step in developing a successful malaria vac-
cine. The COOH-terminal fragment of MSP1 has been
evaluated as a leading candidate for the malaria vaccine, and
BCG has been recognized to have a prominent adjuvant
effect. Based on our aim to combine the two, we con-
structed rBCG which expressed MSP1-15 as a fusion pro-
tein with a-k. a-k is a secretory protein of M. kansasii;
consequently, the fusion protein was expected to be se-
creted from BCG. The results of Western blotting revealed
that MSP1-15 was secreted as a fusion protein, with a simi-
lar antigenic conformation as the native COOH-terminal
fragment of MSP1-15 with two epidermal growth factor–
like domains (Fig. 1 C).
Among the proteins of blood-stage Plasmodium, MSP1
has been studied the most intensively as a potential target
for protective immunity. Two antibody-dependent mecha-
nisms have been reported for protection by immunization
with MSP1 against P. falciparum cultured in vitro. One is
interruption of parasite invasion into erythrocytes by anti-
bodies to the COOH-terminal fragment of MSP1 (35), and
the other is inhibition of secondary processing of MSP1 by
antibodies (42). Studies supporting antibody-dependent
protection induced by MSP1 were reported in the rodent
model (50, 51). However, other experiments showed that
protection induced by vaccination with MSP1 did not cor-
relate with antibody levels or in vitro growth inhibition as-
say, using MSP1-immunized sera in rodent (52) and pri-
mate models (32, 34, 53). No protective efficacy against P.
falciparum was observed in the Aotus monkey, though a
high titer of MSP1-specific antibody was produced (54).
These data suggest that protective mechanisms may vary
depending on the immunization protocol and the animals.
They also indicate that immunization with MSP1 induced
protective effectors other than antibody. High levels of an-
tibody against MSP1-15 before challenge were observed in
mice immunized with GST–MSP1-15 in artificial adju-
vants (Fig. 5 C). However, the sera did not induce protec-
tion in vivo (Fig. 6 B). Furthermore, rBCGMSP1-15 im-
Figure 6. Analysis of sera after
challenge. (A) Isotype distribu-
tion of antibodies against P. yoelii
lysate. Serum antibodies ob-
tained from surviving mice,
which had been preimmunized
with rBCGMSP1-15, were as-
sayed for the level of Igs and
their distribution into IgM,
IgG1, IgG2a, IgG2b, and IgG3
subclasses using anti–mouse sub-
class-specific antibodies. Sera
were diluted to 1:100. Each
point represents the average of
six surviving animals. (B) Passive
immunity imparted by transfer of
each serum. Sera from C3H/He
mice immunized with rBCGMSP1-15 were transferred into groups of
four mice before parasite challenge (left) and after clearance of infection
(right). Each line shows the course of parasitemia of an individual mouse.
y-axis, Percentage of parasitemia. x-axis, Days from infection. d, Dead
mice. s, Self-cured mice.
Figure 7. Correlations among cytokine
production (A), antibody subclass (B), and
protective efficacy induced by immuniza-
tion with MSP1-15 (C). (A) Production of
IFN-g in spleen cells stimulated with con-
trol saline (gray bar), MBP (black bar), and
MBP–MSP1-15 (white bar). y-axis, Amounts
of produced cytokines in supernatants. Im-
munizing samples are indicated below the
x-axis. Protocol of IFN-g measurement is
described in Materials and Methods. Assay
was performed in duplicate with indepen-
dent samples; values shown are the averages.
(B) The antibody levels against MBP–
MSP1-15 and their isotype distribution in
sera from A/J (left) or C57BL/6 (right) mice
immunized with GST (black bar) or GST–
MSP1-15 (white bar) were analyzed by
ELISA. (C) Parasitemia curves of P. yoelii in
A/J (left) and C57BL/6 (right) mice which
had been immunized with GST (X) or
GST–MSP1-15 (filled circle) in RAS were estimated from Giemsa-stained smears. Each line shows the course of parasitemia of an individual mouse. y-axis,
Percentage of parasitemia. x-axis, Days after infection. d, Dead mice. s, Self-cured mice.851 Matsumoto et al.
munization, which was more effective than artificial
adjuvants (Fig. 2), did not produce an obvious MSP1-15–
specific antibody before P. yoelii infection (Fig. 5 A). These
results indicated that protective efficacy by MSP1-15 im-
munization did not depend on the MSP1-15–specific anti-
body, at least at the beginning of infection, in our study.
rBCGMSP1-15 immunization induced more efficient
protection in mice than artificial adjuvant systems (Fig. 2).
An appreciable amount of IFN-g was detected when
spleen cells from mice immunized with rBCGMSP1-15
were stimulated with MSP1-15 (Fig. 3). Neutralization of
IFN-g at the early stage of P. yoelii infection reduced pro-
tection. A correlation between protection and production
of MSP1-15–specific IFN-g was observed when A/J and
C57BL/6 mice were immunized with GST–MSP1-15 in
RAS (Fig. 7). Immunization with rBCGMSP1-15 also
protected A/J mice but not C57BL/6 mice, though only
parental BCG immunization prevented the death of A/J
mice (data not shown). Together, these data indicated that
IFN-g has an important role in the protection induced by
MSP1-15 immunization. IFN-g, which is expected to be
produced by several kinds of cells, such as the Th1-type T
lymphocyte, CD81 T lymphocyte, and natural killer cell,
mediates cellular immunity by activation of macrophages
and enhancement of killing of intracellular organisms (55).
IFN-g also enhances production of NO, which is effective
against intracellular parasites (56). It was reported previously
that the level of IFN-g in the sera of monkeys immunized
with MSP1 correlated with protection against P. falciparum
(34). The mechanisms of protection against the blood-stage
malaria parasite were studied extensively in the Plasmodium
chabaudi model using a nonlethal strain (57–60). Those stud-
ies revealed that the Th1-type immune response, including
IFN-g and NO, induced protection against P. chabaudi.
Cellular immunity such as the mononuclear phagocytic sys-
tem played an important role in protective immunity against
intraerythrocytic asexual stages of parasites (61, 62). One of
the contributions of MSP1-15–specific IFN-g for this pro-
tection may be to enhance the killing of parasites by activa-
tion of the cellular immune response.
In this study, passive transfer experiments showed that
sera from self-cured mice after infection were protective
(Fig. 6 D), and that the major antibody subclass of the pro-
tective sera was IgG2a (Fig. 5 B). The IgG2a subclass anti-
body is cytophilic and shows extensive complement-fixing
ability. This cytophilic antibody promotes phagocytosis,
antibody-dependent cell-mediated cytotoxicity, and anti-
body-dependent cellular inhibition. It has been implicated
in antibody-mediated protective immunity against blood-
stage P. falciparum in vitro (61). The isotype content of sera
from individuals with defined clinical states of resistance or
susceptibility to malaria has been investigated in several
tropical countries. Those studies also revealed that the cy-
tophilic antibody subclasses predominated in protected sub-
jects (63–65). It has also been reported that the antibody
was necessary to eliminate a blood-stage malaria parasite in-
fection (66). Together, these suggest that the cooperation
of cytophilic antibody and cell-mediated cytotoxicity is ef-
fective for attacking parasites, and that such an immune re-
sponse might eventually eradicate the parasites. It is believed
that IgG2a is the antibody induced by B lymphocytes stim-
ulated with IFN-g. In this experiment, one of the contri-
butions of MSP1-15 to protection may be to enhance
smooth production of protective IgG2a antibodies by IFN-g
stimulation.
In summary, the most important contribution of this
study is that we first succeeded in inducing a strong degree
of protection against Plasmodium infection using rBCG and
found that live BCG is the superior adjuvant for a malaria
vaccine. The second most important contribution is that
IFN-g plays an important role in the protection induced by
MSP1-15 regardless of the adjuvants used to date; it may
stimulate the cellular immune response and the production
of protective antibodies against the protective antigens of
parasites. Thus, we found that both cellular and humoral
immune responses were essential for protection against dis-
ease. BCG induces strong cellular immunity and has been
used all over the world. Therefore, a combination of BCG
and parasite antigens may be the best system, and can be
safely used in humans. This study is likely to have wide-
ranging implications for efforts to develop an effective vac-
cine against blood-stage Plasmodium.
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